Technology & Society
Here’s an article by the folks at Longevity Technology that explains a bit about what I’ve been up to lately with 100 Plus Capital. “While longevity is now seeing increasing interest from major Silicon Valley investment firms, companies in our
I’ll be moderating a longevity panel tomorrow at the JPM conference in San Francisco. Panelists include: -Kristen Fortney, founder and CEO of BIOAGE, a biotechnology startup that discovers and develops proprietary drugs to treat aging and associated diseases. -Aydin Senkut,
Check out my conversation on investing in human longevity with @tamccann and the L200 crew! During this podcast we explore a number of interesting topics, including: What has changed since I wrote 100 Plus Why longevity is good for economic
Great news — I wonder how low sequencing costs can go. From Fierce Biotech: “Oxford Nanopore Technologies (ONT) has tapped a global syndicate of investors for $140 million to fuel its attempts to upend the genome sequencing market. The financing
I’ll be moderating a longevity panel tomorrow at VLAB. VLAB is the San Francisco Bay Area chapter of the MIT Enterprise Forum, a global non-profit organization dedicated to connecting Silicon Valley’s entrepreneurs, industry experts, venture capitalists, private investors and technologists
Here’s the story in Forbes: “What if a simple blood test could detect any cancer early, when it was still easy to treat? It sounds like science fiction. But Illumina ILMN -0.61%, the $24 billion (market cap) biotechnology company that
From Nature: “Wyss-Coray formed a start-up company, Alkahest in Menlo Park, California, and in September 2014 it began a randomized, placebo-controlled, double-blind trial at Stanford, testing the safety and efficacy of using young plasma to treat Alzheimer’s disease. Six out
It’s still a long way away, but this is a great idea (and from Singularity University). From Wired: “A new startup, dubbed Miroculus, is building a device that could easily and affordably check for dozens of cancers using a single
From the Verge: “The Google-backed life-extension company, Calico, announced today that it was partnering with Chicago-based pharmaceutical giant AbbVie to develop and bring to market new drugs targeting diseases associated with old age. Each partner has committed to providing $250
Here’s a piece I wrote for Slate. “Silicon Valley, known for entrepreneurs, gadget lovers, and paradigm breakers, has recently turned its attention towards longevity, powering an important cultural change on the topic. The interests of these movers and shakers run
The Financial Times posted an interesting article about Craig Venter and his new longevity company, Human Longevity Inc. When the journalist asks him if his company is in competition with Google’s Calico (also set up to extend human healthspan), Venter